Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLINTHERA.2007.01.015PMID 17379054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

  2006cited by this paper
• Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice

  2006cited by this paper
• Incretin mimetics as a novel therapeutic option for hepatic steatosis

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

  2005cited by this paper
• Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage

  2005cited by this paper
• Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.

  2005cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper
• The fatty liver and insulin resistance.

  2005cited by this paper
• Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

  2004cited by this paper
• Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

  2004cited by this paper
• Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

  2004cited by this paper
• The epidemic of obesity.

  2004cited by this paper
• Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.

  2004cited by this paper
• Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

  2004cited by this paper
• Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

  2003cited by this paper
• Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

  2003cited by this paper
• Obesity and type 2 diabetes.

  2003cited by this paper
• Weight Effect of Current and Experimental Drugs for Diabetes Mellitus

  2003cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

  2003cited by this paper
• Current best treatment for non-alcoholic fatty liver disease

  2003cited by this paper
• Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

  2003cited by this paper
• Clinical practice. Initial management of glycemia in type 2 diabetes mellitus.

  2002cited by this paper
• Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels

  2002cited by this paper
• Initial Management of Glycemia in Type 2 Diabetes Mellitus

  2002cited by this paper
• Diabetes trends in the USA

  2002cited by this paper
• American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease.

  2002cited by this paper
• AGA technical review on nonalcoholic fatty liver disease.

  2002cited by this paper
• Metformin: An Update

  2002cited by this paper
• Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

  2001cited by this paper
• Combination therapies with insulin in type 2 diabetes.

  2001cited by this paper
• American Gastroenterological Association. Our new president--Jon I. Isenberg, M.D.

  2001cited by this paper
• Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats.

  2000cited by this paper
• Intentional weight loss and mortality among overweight individuals with diabetes.

  2000cited by this paper
• Diabetes trends in the U.S.: 1990-1998.

  2000cited by this paper
• Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.

  2000cited by this paper
• Long-Term Prevention of Bone Loss

  2000cited by this paper
• Pharmacologic Therapy for Type 2 Diabetes Mellitus

  1999cited by this paper
• Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

  1999cited by this paper
• UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects.

  1997cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2583–2589 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2004-0535 Medical Consequences of Obesity

  year unknowncited by this paper

• Exploring Side Effects and Discontinuation Reasons of Glucagon-Like-Peptide-1 Agonist (Liraglutide, Semaglutide) for Weight Loss Among Patients at King Abdulaziz University, Jeddah in 2021 to 2023

  2025cites this paper
• Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis

  2025cites this paper
• GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance.

  2025cites this paper
• GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity

  2025cites this paper
• Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon

  2024cites this paper
• The hypothalamus as the central regulator of energy balance and its impact on current and future obesity treatments

  2024cites this paper
• GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment

  2024cites this paper
• Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives

  2023cites this paper
• Medical Weight Optimization for Arthroplasty Patients: A Primer of Emerging Therapies for the Joint Arthroplasty Surgeon.

  2023cites this paper
• GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

  2023cites this paper
• The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

  2023cites this paper
• Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue

  2022cites this paper
• Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

  2022cites this paper
• Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

  2022cites this paper
• Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know

  2022cites this paper
• Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease

  2022cites this paper
• Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective

  2021cites this paper
• Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?

  2021cites this paper
• Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes

  2021cites this paper
• Application in medicine: obesity and satiety control

  2021cites this paper
• Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management

  2021cites this paper
• The pathophysiology of gut–liver connection

  2021cites this paper
• Aversion to Off-Label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard.

  2021cites this paper
• Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH

  2020cites this paper
• Comparison Between Sleeve Gastrectomy and Exenatide on Type 2 Diabetic Patients

  2020cites this paper
• Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential

  2020cites this paper
• GLP1 agonists beyond glycemic control—redefining their role

  2020cites this paper
• Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice

  2020influential citation
• Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review

  2020cites this paper
• Growth differentiation factor 15 as a potential therapeutic for treating obesity

  2020cites this paper
• Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming

  2020cites this paper
• Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review

  2020cites this paper
• Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit

  2019cites this paper
• Incretin Hormones in the Control of Immunometabolism

  2019cites this paper
• Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force

  2019cites this paper
• Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers.

  2019cites this paper
• Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.

  2018cites this paper
• Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

  2018cites this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018influential citation
• The relationship between serum dipeptidyl peptidase-4 enzyme and nonalcoholic fatty liver disease in diabetic and nondiabetic patients

  2018cites this paper
• Pharmacotherapy of type 2 diabetes: An update.

  2018cites this paper
• Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

  2018cites this paper
• Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials

  2018cites this paper
• Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

  2018cites this paper
• Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

  2018cites this paper
• GLP1 als Therapieoption bei Adipositas (kurz- und langwirksame GLP1 Analoga im klinischen Vergleich)

  2018influential citation
• Therapies in non‐alcoholic steatohepatitis (NASH)

  2017cites this paper
• Liraglutide

  2017cites this paper
• Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment

  2017cites this paper
• GLP-1 receptor agonists in NAFLD.

  2017cites this paper
• Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study

  2016cites this paper
• Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

  2016cites this paper
• Approach to diabetes management in patients with CVD.

  2016cites this paper
• Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.

  2016cites this paper
• Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

  2016cites this paper
• The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide

  2016cites this paper
• Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.

  2016cites this paper
• Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.

  2016cites this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists on β-Cell Function in Patients with Type 2 Diabetes

  2016cites this paper
• New Approaches to Feline Diabetes Mellitus

  2016cites this paper
• Lipid Lowering Effect of Anti Diabetic Agents-Recent Research

  2015cites this paper
• Endocrine causes of nonalcoholic fatty liver disease.

  2015cites this paper
• Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

  2015cites this paper
• A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT

  2015cites this paper
• Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

  2015cites this paper
• Substituted furopyridinediones as novel inhibitors of α-glucosidase

  2015cites this paper
• Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

  2015cites this paper
• Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

  2015cites this paper
• Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms

  2015cites this paper
• Design and Synthesis of Pyrazole-3-one Derivatives as Hypoglycaemic Agents

  2015cites this paper
• Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

  2015cites this paper
• A concise review of non-alcoholic fatty liver disease.

  2015cites this paper
• Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making

  2014cites this paper
• Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

  2014cites this paper
• Exendin-4 effects on islet volume and number in the mouse pancreas.

  2014cites this paper
• Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes

  2014cites this paper
• Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report

  2014cites this paper
• Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.

  2014cites this paper
• Protein chip-based GLP-1 receptor assay system

  2014cites this paper
• Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

  2014cites this paper
• Use of exenatide and liraglutide in Denmark: a drug utilization study

  2014influential citation
• Therapeutic Class Overview Attention Deficit/Hyperactivity Disorder (ADHD) Agents and Stimulants

  2014cites this paper
• Glucagon-like peptide-1 in nonalcoholic steatohepatitis

  2014cites this paper
• The role of incretin-based therapies in prediabetes: a review.

  2014cites this paper
• Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

  2014cites this paper
• Nonalcoholic fatty liver disease Incretin based therapies : A novel treatment approach for non-alcoholic fatty liver disease

  2014cites this paper
• Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications

  2014cites this paper
• Adverse Effects of GLP-1 Receptor Agonists.

  2014cites this paper
• DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus

  2014cites this paper
• Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study

  2014cites this paper
• The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.

  2014cites this paper
• The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus.

  2014cites this paper
• AN OVERVIEW OF PHARMACOTHERAPY OF OBESITY: AN UPDATE

  2013cites this paper
• Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea

  2013cites this paper
• Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment

  2013cites this paper
• Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program

  2013influential citation
• Reducing the Risk of Obesity: Defining the Role of Weight Loss Drugs

  2013cites this paper
• Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension

  2013cites this paper
• The Incretin Mimetics

  2013cites this paper
• Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.

  2013cites this paper